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a b s t r a c t
The APOBEC family of single-stranded DNA cytosine deaminases comprises a formidable arm of the vertebrate
innate immune system. Pre-vertebrates express a single APOBEC, whereas somemammals produce as many as
11 enzymes. The APOBEC3 subfamily displays both copy number variation and polymorphisms, consistent
with ongoing pathogenic pressures. These enzymes restrict the replication of many DNA-based parasites, such
as exogenous viruses and endogenous transposable elements. APOBEC1 and activation-induced cytosine
deaminase (AID) have specialized functions in RNA editing and antibody gene diversiﬁcation, respectively,
whereas APOBEC2 and APOBEC4 appear to have different functions. Nevertheless, the APOBEC family protects
against both periodic viral zoonoses as well as exogenous and endogenous parasite replication. This review
highlights viral pathogens that are restricted by APOBEC enzymes, but manage to escape through unique
mechanisms. The sensitivity of viruses that lack counterdefense measures highlights the need to develop
APOBEC-enabling small molecules as a new class of anti-viral drugs.
& 2015 Elsevier Inc. All rights reserved.
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APOBEC hallmarks
DNA deamination
The fundamental biochemical activity of the APOBEC family of
enzymes is DNA cytosine deamination (Fig. 1A). This activity was
originally demonstrated using Escherichia coli-based mutation
assays, and subsequently elaborated in a wide variety of biochemical
and virological experimental systems (Harris et al., 2002; Petersen-
Mahrt et al., 2002; reviewed by Aydin et al. (2014), Desimmie et al.
(2014), Di Noia and Neuberger (2007), Feng et al. (2014), Imahashi
et al. (2012), Malim and Bieniasz (2012), Refsland and Harris (2013),
Shandilya et al. (2014) and Strebel (2013)). APOBEC cytosine to uracil
(C-to-U) deaminase activity is largely speciﬁc to single-stranded
DNA substrates and requires a minimum of ﬁve contiguous deoxy-
nucleotides (three bases on the 50 side of the target cytosine and one
on the 30 side) (Harjes et al., 2013; Nabel et al., 2013). DNA C-to-U
deamination occurs through a zinc-mediated hydrolytic mechanism,
in which a conserved glutamic acid deprotonates water, and the
resulting zinc-stabilized hydroxide ion attacks the 4-position of the
cytosine nucleobase, with the net replacement of the amine group
(NH2) with a carbonyl group (double-bonded oxygen) (Fig. 1A).
A second hallmark property of the APOBEC enzymes, which has
been exploited to deduce biological functions, is an intrinsic local
dinucleotide preference, with one enzyme preferring the target
cytosine to be preceded by a purine (AID), one preferring the target
cytosine to be preceded by another cytosine (APOBEC3G), and the
remainder preferring the target cytosine to be preceded by a thymine
(APOBEC1, APOBEC3A/B/C/D/F/H) (Carpenter et al., 2010; Kohli et al.,
2010; Rathore et al., 2013; Wang et al., 2010 and references therein).
APOBEC2 and APOBEC4 cannot be classiﬁed this way because they
have yet to elicit activity. Chimeric enzymes constructed by swapping
domains between proteins of different speciﬁcity have been particu-
larly informative by implicating amino acid residues in a loop
adjacent to the active site in governing these minus-one nucleobase
preferences (loop 7; described in greater detail below). Although
these enzymes may be grouped by dinucleotide preferences, it is
important to note that the identities of the single-stranded DNA
substrate minus-two and plus-one bases are also inﬂuential and that
other factors such as DNA integrity and secondary structures may
also be key determinants (references above and Holtz et al., 2013;
Nabel et al., 2013; Rausch et al., 2009; Yu et al., 2004).
Globular protein organization
Considerable high-resolution structural information is now avail-
able for several human APOBEC family members including APOBEC3A
(A3A), APOBEC3C (A3C), APOBEC3F (A3F), and APOBEC3G (A3G)
(most recent structures by Bohn et al. (2013), Byeon et al. (2013),
Kitamura et al. (2012), Li et al. (2012b) and Siu et al. (2013) and older
work referenced therein; reviewed recently by Feng et al. (2014),
Refsland and Harris (2013), Salter et al. (2014), Shandilya et al. (2014)
and Siu et al. (2013)). Each APOBEC family member is comprised of
either one or two conserved zinc-coordinating domains and, in the
case of the double-domain enzymes, the two halves are most likely
joined by a ﬂexible linker.
The C-terminal catalytic domain of A3G illustrates several of the
family's structural hallmarks (Fig. 1B). First, each deaminase domain
has an overall globular architecture comprised of ﬁve β-strands and
six α-helices. The β-strands are organized into a hydrophobic
β-sheet core, and the α-helices are positioned around this core. β2
is split in A3G into β2 and β20 but this feature is shorter or
continuous in A3A, A3C, and A3F. The loops between secondary
structure elements vary in length, composition, and conservation
and are thought to have key roles in nucleic acid binding, local target
selection, and overall function. Second, the catalytic site is charac-
terized by a glutamate and a histidine in an HxE motif located at the
end of a conserved α-helix and two cysteines in a CPx2-4C motif at
the end of an adjacent conserved α-helix, which serves to coordinate
a single zinc ion (α2 and α3 based on N- to C-terminal numbering of
secondary structural elements; x represents a less conserved amino
acid; Fig. 1B). These α-helices are anchored into the globular
structure through a conserved β-strand located in the center of a
hydrophobic β-sheet that comprises the core of each domain. Each
α–β–α catalytic motif is encoded by a single exon that most likely
evolved (and continues to evolve) as a contiguous block enabling
each of the ﬁve distinct APOBEC subgroups to be distinguished
(elaborated below). This core α–β–α catalytic motif is most likely
derived from the more ancient RNA and/or free-base deaminating
enzymes (Chen et al., 2008; Conticello, 2008; Prochnow et al., 2007).
Finally, high-resolution information of the non-catalytic domain of
A3G and other double-domain enzymes is still lacking, but strong
homology with the solved catalytic domain structures, including no
signiﬁcant insertions or deletions, indicates that they will have a
similar overall structural organization.
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Fig. 1. APOBEC hallmarks. (A) A schematic of the single-stranded DNA cytosine deamination reaction catalyzed by APOBEC family members. (B) A ribbon model of the A3G
catalytic domain showing its globular structure and a blow-up of the zinc-coordinating active site (cysteines are depicted in yellow, histidine in blue, and the catalytic
glutamate in red). (C) Schematics of the A3 gene composition of several current mammals depicted above the repertoire of a likely common ancestor and current non-
mammalian vertebrates. The color scheme distinguishes phylogenetic subfamilies. See the text for additional details.
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Positive selection and copy number variation
One of the most fascinating hallmarks of the APOBEC family
and a probable characteristic of many virus restriction factors is
rapid evolution evidenced by elevated rates of amino acid sub-
stitution mutations and gene copy number variations (Harris et al.,
2012; Johnson and Sawyer, 2009; Meyerson and Sawyer, 2011;
Ortiz et al., 2006). A higher ratio of amino acid altering mutations
relative to silent mutations is called positive selection. All of the A3
subfamily members show compelling evidence for positive selec-
tion (Duggal et al., 2013; Henry et al., 2012; Sawyer et al., 2004;
Zhang and Webb, 2004), consistent with ancient and likely
ongoing battles with viral pathogens. There is also tremendous
variation in A3 gene copy number between branches of the
mammalian phylogenetic tree (Conticello et al., 2005; Harris and
Liddament, 2004; LaRue et al., 2009; LaRue et al., 2008; Münk et
al., 2008) (Fig. 1C). For instance, humans, chimpanzees, and rhesus
macaques, and most other primates share a similar seven gene A3
locus comprised of three single domain genes (A3A/C/H) and four
double domain genes (A3B/D/F/G) (Hultquist et al., 2011; Schmitt
et al., 2011; Virgen and Hatziioannou, 2007). In contrast, mice have
just one double-domain A3 gene (Harris and Liddament, 2004; Li
et al., 2012a; Sanville et al., 2010). Other present day mammals
have different copy numbers and overall gene organizations
(Conticello et al., 2005; Harris and Liddament, 2004; LaRue et al.,
2008, 2009; Münk et al., 2008).
Genomic sequences have enabled investigators to deduce that
the origin of the mammal-speciﬁc A3 gene subfamily most likely
occurred through duplication of an ancestral AID/APOBEC1 locus
(these genes are still located adjacent to one another in most
vertebrates, but separated in others, such as primates, by a large
chromosomal inversion) (Conticello et al., 2005; Harris and
Liddament, 2004; LaRue et al., 2008, 2009). The tandem head-
to-tail organization of the ancestral A3 gene cluster provided the
necessary substrate for rapid evolutionary diversiﬁcation through
multiple unequal crossing-over events, with some leading to
gene expansions and others to contractions. Selective pressures
from diverse viral infections most likely led to the expanded A3
gene repertoire observed in many present day mammals. Never-
theless, deletions are also common as observed by one A3 gene in
rodents (due to a relatively ancient deletion early in the rodent
lineage) and one in pigs (due to a relatively recent deletion
speciﬁc to the Suidae lineage). Copy number and amino acid
alternations also occur within a single species evidenced by the
circulation of a common A3B deletion in humans (Kidd et al.,
2007), the existence of seven distinct A3H haplotypes in humans
that encode stable or unstable proteins (OhAinle et al., 2008;
Ooms et al., 2013; Refsland et al., 2014; Wang et al., 2011), two
human A3A translation initiation sites (Henry et al., 2012;
Stenglein et al., 2010; Thielen et al., 2010), multiple transcription
initiation sites and alternative splicing events (LaRue et al., 2008;
Lassen et al., 2010; Münk et al., 2008; Santiago et al., 2008), a
polymorphism in mice that affects splicing (exon composition)
(Jónsson et al., 2006; Li et al., 2012a; Sanville et al., 2010), and the
likelihood that many other variants await discovery and func-
tional investigation.
Human APOBEC3 enzymes and HIV restriction
Deaminase-dependent restriction mechanism
Permissive and non-permissive cell fusion experiments deduced
the existence of a dominant cellular factor that blocked the replica-
tion of human immunodeﬁciency virus type 1 (HIV-1) lacking its
viral infectivity factor (Vif) (Madani and Kabat, 1998; Simon et al.,
1998). In 2002, a subtractive hybridization approach yielded a variety
of mRNA species expressed differentially between a permissive T-cell
line called CEM-SS and its non-permissive parental line CEM (Sheehy
et al., 2002). One of these mRNAs (CEM15), independently named
APOBEC3G and commonly abbreviated A3G (Harris et al., 2002;
Jarmuz et al., 2002), was sufﬁcient to convert a permissive cell to a
non-permissive phenotype (Sheehy et al., 2002). After demonstrating
its potent DNA cytosine deaminase activity (Harris et al., 2002), a
viral cDNA deamination mechanism was quickly unraveled (Harris
et al., 2003; Mangeat et al., 2003; Zhang et al., 2003). This work
provided a compelling mechanistic explanation for prior reports of
strand-biased retroviral G-to-A mutation (Pathak and Temin, 1990;
Vartanian et al., 1994; Wain-Hobson et al., 1995).
A3G-focused studies were followed by additional work demon-
strating HIV-1 restriction in model cell-based systems using over-
expression of A3F and multiple other family members (reviewed
by Desimmie et al. (2014), Malim and Bieniasz (2012) and Refsland
and Harris (2013)). However, conﬂicting results were reported for
all human A3 family members over the next decade, with some
studies showing HIV-1 restriction and others not (except A3G).
Therefore, a variety of experimental approaches clariﬁed the role
of APOBEC, including stable A3 expression in permissive T-cell
lines, A3 knockdown and knockout studies in non-permissive
T-cell lines, and Vif separation-of-function experiments in primary
T lymphocytes were used to deduce that the combined activities of
A3D, A3F, A3G, and A3H are responsible for HIV-1 restriction and
G-to-A mutagenesis (Hultquist et al., 2011; Ooms et al., 2013;
Refsland et al., 2012, 2014 and references therein).
The current model for HIV-1 restriction is shown in Fig. 2
(adapted from Harris et al. (2012)). In the absence of Vif, A3D, A3F,
A3G, and/or A3H forms cytoplasmic ribonucleoprotein complexes
with HIV-1 Gag and one or more cellular RNA species (7SL, Y1, and
viral genomic RNA have been implicated; Apolonia et al., 2015;
Bogerd and Cullen, 2008; Strebel and Khan, 2008; Tian et al., 2007;
Wang et al., 2007, 2008; Zhen et al., 2012). RNA binding requires the
nucleocapsid domain of Gag (although heterologous RNA-binding
proteins can substitute), and the importance of an RNA bridge is
highlighted by several studies showing the sensitivity of Gag–A3
complexes to RNase A treatment (Alce and Popik, 2004; Apolonia et
al., 2015; Douaisi et al., 2004; Schafer et al., 2004; Svarovskaia et al.,
2004). A3D, A3F, A3G, and A3H have been observed to oligomerize
in living cells, and this property correlates with the capacity to
restrict HIV-1 infectivity (Li et al., 2014). Although precise mechan-
istic details will require additional investigation, RNA–protein inter-
actions clearly mediate the packaging of restrictive A3 enzymes into
assembling HIV-1 particles.
During or shortly after budding and before the conical capsid
becomes fully closed (matures), a signiﬁcant fraction of packaged A3
enzymes enter the viral core (i.e., become encapsidated). This step of
the restriction mechanism is evidenced by chimeric A3 enzymes and
amino acid substitution mutants that package, but somehow fail to
breach the core and inhibit viral infectivity (Donahue et al., 2015;
Haché et al., 2005; Song et al., 2012). Upon receptor binding and
fusion, the conical capsid is deposited in the cytosol of a target cells,
reverse transcription occurs concomitant with RNase H activity to
degrade template viral genomic RNA, and single-stranded viral
cDNA becomes susceptible to the mutagenic activity of an encapsi-
dated A3 enzyme. The viral reverse transcriptase enzyme uses the
resulting viral cDNA uracils to template the insertion of genomic
strand adenines. A single round of virus replication and A3 muta-
genesis can suppress viral infectivity by several logs and convert up
to 10% of all genome plus-strand guanines into adenines, accounting
for the phenomenon of retroviral G-to-A hypermutation (Harris
et al., 2003; Liddament et al., 2004; Mangeat et al., 2003; Yu et al.,
2004; Zhang et al., 2003). Interestingly, although a single viral
genome can be co-mutated by two different A3 enzymes in model
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single-cycle experiments (Liddament et al., 2004), co-mutated
sequences rarely occur in primary HIV-1 isolates, suggesting that
the number of A3 molecules per particle may be low during
pathogenic infections (Ebrahimi et al., 2012; Sato et al., 2014).
Deaminase-independent mechanism
Multiple studies have noted that signiﬁcant HIV-1 restriction can
still occur upon overexpression of catalytically defective variants of
A3G and A3F (Chaurasiya et al., 2014; Holmes et al., 2007a, 2007b;
Iwatani et al., 2007; Newman et al., 2005). This deaminase activity-
independent effect appears to be greater for A3F than for A3G (Albin
et al., 2014; Browne et al., 2009; Holmes et al., 2007a; Kobayashi
et al., 2014; Schumacher et al., 2008). Primary cell studies also
suggest a deaminase-independent component (Gillick et al., 2013). A
number of models have been proposed for this catalytic activity-
independent restriction mechanism including binding genomic RNA
to impede reverse transcription, binding tRNA to prevent reverse
transcription initiation, binding reverse transcriptase directly, and
others (e.g., Gillick et al., 2013; Holmes et al., 2007a; Wang et al.,
2012; reviewed by Holmes et al. (2007b)). However, the prevailing
model to explain this phenomenon is genomic RNA binding, which
causes a steric block to reverse transcription. Because A3G and A3F
are capable of binding both RNA and single-stranded DNA, such
binding effectively diminishes the overall kinetics of reverse
transcription. Interestingly, although a minority of HIV-1 restriction
is attributable to this mechanism, deaminase-independent mechan-
isms appear dominant for A3-mediated restriction of several other
parasitic elements (detailed below).
Vif-mediated counterdefense mechanism
Early studies showed that Vif function was required in virus-
producing, but not in target cells, and that the absence of Vif in the
producer cells somehow resulted in less viral cDNA accumulation
in target cells (Gabuzda et al., 1992; von Schwedler et al., 1993). The
discovery of A3G led rapidly to unraveling the mechanism of Vif-
mediated counterdefense (Conticello et al., 2003; Kao et al., 2003;
Marin et al., 2003; Sheehy et al., 2003; Stopak et al., 2003; Yu et al.,
2003). A major clue was the observation that ﬂuorescently-tagged
A3G appeared brighter in cells without Vif, than in cells co-expressing
Vif (rather than, for instance, re-localization; e.g., Conticello et al.,
2003). Similar decreases in A3G intensity were observed by immuno-
blot comparisons of cell extracts with and without co-expressed Vif
(e.g., Conticello et al., 2003). In both instances, A3G signal could be
recovered by treating cells with proteasome inhibitors such as MG132
(e.g., Conticello et al., 2003). Several groups thereby converged upon a
polyubiquitination and degradation mechanism (Conticello et al.,
2003; Kao et al., 2003; Marin et al., 2003; Sheehy et al., 2003;
Stopak et al., 2003; Yu et al., 2003). Proteomic studies and genetic
experiments implicated an E3 ubiquitin ligase consisting of CUL5,
ELOB, ELOC, and RBX1 (Yu et al., 2003).
Over the ensuing decade, additional progress on Vif function
was made through a wide variety of genetic and virologic studies
but broader progress was constrained due to puriﬁcation issues
that prevented biochemical and structural approaches. Many labs
invested signiﬁcant effort on Vif puriﬁcation in heterologous
systems, such as E. coli, with mostly negative results. Speculating
that this problem may be due to a missing cellular co-factor, a
series of quantitative proteomic experiments revealed the tran-
scription co-factor CBF-β as an abundant Vif-interacting protein
(Jäger et al., 2011; Zhang et al., 2011). CBF-β co-precipitated with
CUL5 and ELOC, but only in the presence of Vif, suggesting
membership in the Vif–ligase complex itself. Indeed, CBF-β
enabled Vif expression in E. coli, and the puriﬁcation of a Vif–
CBF-β ubiquitin ligase complex with polyubiquitination speciﬁcity
for HIV-restrictive (A3G), but not non-restrictive (A3A) enzymes.
Knockdown studies demonstrated that CBF-β was required for Vif
expression and function against restrictive A3 enzymes. These
advances led to a revised model for Vif-mediated A3 counteraction
in which Vif hijacks CBF-β to nucleate the formation of an active
ubiquitin ligase complex that protects HIV-1 from lethal restriction
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(Fig. 2). Many aspects of this model, including an extensive
interface between Vif and CBF-β, have been validated recently
through the ﬁrst X-ray crystal structure of the HIV-1 Vif ligase
complex (Guo et al., 2014).
Conservation of the A3 restriction and Vif counteraction mechanisms
As described above, all mammals encode at least one A3 and
often multiple A3s. The A3-mediated restriction mechanism is
conserved since enzymes from many different mammals elicit retro-
virus restriction activity (frequently against HIV-1 or HIV-based
vectors). However, lentiviruses are only known to exist in a small
subset of mammals. A comprehensive examination of restriction and
Vif-mediated counteraction activities using host A3 enzymes and
HIV-1, simian immunodeﬁciency virus (SIV) mac239, feline immu-
nodeﬁciency virus (FIV), bovine immunodeﬁciency virus (BIV), and
maedi-visna virus (MVV) Vif proteins demonstrated conservation of
both mechanisms (LaRue et al., 2010). As expected, each Vif protein
selectively degraded the A3 enzyme of its lentiviral host. However,
some cross degradation was observed as might also be expected
because the A3 enzymes are relatively conserved (especially in
comparison to Vif). Surprisingly, recent work has demonstrated that
CBF-β is speciﬁcally required for function of primate lentiviral Vif
proteins, but not for non-primate Vifs (Ai et al., 2014; Han et al., 2014;
Yoshikawa et al., 2014; Zhang et al., 2014). These data indicate that
either the Vif proteins of FIV, BIV, and MVV do not require a CBF-β-
like factor, or these viruses have evolved to use one or more other as-
yet-unknown cellular factors. Additional work will be needed to
distinguish between these intriguing possibilities.
Evidence for HIV-1 restriction and hypermutation in vivo
Prior to the discovery of APOBEC3 enzymes and the elucidation
of HIV-1 Vif counteraction mechanism, many studies reported
strand-biased G-to-A mutations in patient-derived viral sequences
(e.g., Janini et al., 2001; Vartanian et al., 1994; Wain-Hobson et al.,
1995). These and other reports have combined to suggest that
multiple A3 enzymes can impact the virus in vivo. This is clearly
evidenced by the fact that both 50-GG-to-AG and 50-GA-to-AA
mutations are observed in patient-derived sequences and in viral
sequences from humanized models (i.e., A3G and A3D/F/H attribu-
table mutations; Krisko et al., 2013; Sato et al., 2014). However,
because these data rely on standard nucleic acid puriﬁcation and
PCR ampliﬁcation procedures, which survey all available substrates,
it is possible that these hypermutations represent dead-end replica-
tion intermediates that may never have completed reverse tran-
scription and resulted in a productive infection. In other words,
some fraction of these sequences are genetic dead-ends that may
never have been propagated regardless of APOBEC (i.e., interesting
artifacts recovered through technology). This possibility is supported
by far fewer viral G-to-Amutations observed in analyses of viral RNA
in sera (from virus or virus-like particles) compared to viral DNA
from cells of infected individuals (integrated or non-integrated viral
DNA sequences; e.g., Sato et al., 2014).
Considerable effort has therefore been invested in characteriz-
ing viral and/or host genetic variations in an attempt to gauge the
impact of the A3 restriction mechanism in vivo. Host genetic
studies have the potential to be especially informative. However,
most studies have shown conﬂicting effects or a clean negative
result. For instance, a deletion of the full A3B gene that is common
in some Southeast Asian populations provided an opportunity to
unambiguously show that the encoded protein is not a factor in
HIV-1 infection rates, viral loads, and CD4-positive T cell counts,
and has no measurable effect on virus replication in primary cells
ex vivo (Imahashi et al., 2014). In contrast, recent studies compar-
ing stable and unstable A3H proteins have indicated that some
naturally occurring viral variants with hypo-functional Vif alleles
may be susceptible to restriction by stable A3H enzymes (Ooms
et al., 2013; Refsland et al., 2014). Moreover, HIV-1 loads appeared
lower and T cell counts higher overall in patients with stable A3H
proteins in comparison to those with unstable proteins, suggesting
that A3H may help to control viral pathogenesis in vivo (Ooms
et al., 2013). Additionally intriguing is that a signiﬁcant subset of
global HIV-1 isolates may have Vif proteins that are speciﬁcally
hypofunctional toward A3H because a large proportion of the
human population is homozygous for unstable A3H haplotypes,
therefore exerting little or no selective pressure to maintain full Vif
function (Refsland et al., 2014). Given the potential potency of A3-
mediated HIV-1 restriction and the plethora of circulating haplo-
types, these enzymes should be further investigated as candidate
factors in long-term non-progression, elite control, and overt
resistance to infection.
HIV-1 drug resistance studies have also provided valuable portals
into understanding the potential impact of A3 enzymes in vivo.
Several common antiretroviral drug resistance mutations are poten-
tial A3-mediated G-to-A events (Berkhout and de Ronde, 2004;
Haché et al., 2006; Jern et al., 2009; Kim et al., 2010, 2014; Mulder
et al., 2008; Pillai et al., 2008; Sadler et al., 2010). For instance, deep-
sequencing studies have revealed that drug resistance mutations are
more common in HIV-1 cultures in the presence of A3G than in its
absence, and that potential A3-mediated drug resistance mutations
pre-exist in clinical HIV-1 populations (Kim et al., 2010; Mulder et al.,
2008). In addition, adaptive immune responses exert strong selec-
tive pressures on HIV-1, and sequencing studies have shown that
many putative immune escape mutants correspond to potential
A3-mediated G-to-A editing sites (Kim et al., 2014). Finally, signiﬁ-
cant proportions of transmission-associated mutations also corre-
spond to potential A3-mediated G-to-A mutation events (Wood et
al., 2009). These mutations may have been required for escaping
immune responses and/or adapting to differences in host factor
compositions (restriction or dependence factors) during or shortly
after transmission. Taken together, these studies strongly implicate
A3 mutagenesis in providing HIV-1 with mutational fuel and
evolutionary diversity upon which natural adaptive immune and
pharmacologic pressures may act. As detailed below, many concepts
in APOBEC restriction extend far beyond HIV-1 to multiple DNA
parasites.
Human APOBEC3 enzymes and HTLV-1 restriction
HTLV-1 restriction
Cell culture over-expression experiments have indicated that
multiple A3 enzymes can restrict the infectivity of human T-cell
leukemia virus type 1 (HTLV-1) (Derse et al., 2007; Mahieux et al.,
2005; Navarro et al., 2005; Ooms et al., 2012; Sasada et al., 2005;
Strebel, 2005). However, in head-to-head experiments, HTLV-1
appears considerably more resistant than HIV-1 to restriction by
A3D, A3F, and A3G (Derse et al., 2007; Navarro et al., 2005; Ooms
et al., 2012). Only stably expressed haplotypes of A3H caused
strong restriction of both viruses (Ooms et al., 2012). HTLV-1 also
appeared preferentially susceptible to restriction by A3A and A3B
(Ooms et al., 2012). Both deaminase-dependent and independent
mechanisms have been noted (Derse et al., 2007; Mahieux et al.,
2005; Navarro et al., 2005; Ooms et al., 2012; Sasada et al., 2005;
Strebel, 2005). The impact of these enzymes on HTLV-1 infectivity
in primary lymphocytes has yet to be examined in part due to
technical challenges of lower virus infectivity and strong prefer-
ences for cell-to-cell, rather than cell-free transmission.
However, in contrast HIV-1 sequences derived from patient
samples, characteristic G-to-A mutations are relatively rare in
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HTLV-1 sequences. An initial study of HTLV-1 in 10 patients found
no evidence for hypermutation (Mahieux et al., 2005). A subse-
quent larger study analyzed the entire sequence of HTLV-1
proviruses from 60 adult T-cell leukemia (ATL) patients and 10
HTLV-1 carriers and found inactivating mutations in nearly 50% of
cases with G-to-A changes in an A3G context accounting only for a
small subset of nonsense changes (Fan et al., 2010). These
observations are consistent with the fact that HTLV-1 provokes
strong cytotoxic T cell responses in vivo, which often select for
mutational inactivation of dominant viral epitopes encoded by
plus-strand genes such as Tax (Bangham et al., 2014). This
manifests in ATL as oligoclonally expanded pools of T cells, with
each pool characterized by a single replication-defective provirus
insertion (Bangham et al., 2014).
A3 counteraction mechanism of HTLV-1
As mentioned above, HTLV-1 is relatively resistant to restriction
by A3G, in comparison to Vif-deﬁcient HIV-1 (Derse et al., 2007;
Navarro et al., 2005; Ooms et al., 2012). This resistance phenotype
correlated with lower levels of encapsidated A3G. An elegant
mutational analysis revealed that resistance was not due to a viral
accessory protein, rather to a unique C-terminal extension of the
viral nucleocapsid (NC) protein (Derse et al., 2007). If 20 residues of
this extension were deleted or mutated, then HTLV-1 became
exquisitely sensitive to A3G restriction through an encapsidation
and hypermutation mechanism analogous to that described above
for Vif-deﬁcient HIV-1. This work was signiﬁcant by its demonstra-
tion of a novel mechanism of A3 resistance by exclusion. Thus, other
potentially susceptible DNA parasites may use a similar exclusion
mechanism or possess a novel strategy for preventing A3 enzymes
from attacking single-stranded DNA replication intermediates.
Retrovirus restriction by murine A3 – in vivo insights from
animal models
MMTV restriction
The ﬁrst direct evidence that APOBEC family members protect
against retroviral infection in vivowas obtained by studying mouse
mammary tumor virus (MMTV) infection of A3-defective mice
(Okeoma et al., 2007). A3 mRNA is detectable in a wide variety of
wild-type mouse tissues with the highest levels occurring in the
thymus and lymph nodes, suggesting preferential activity in
lymphoid tissues (Okeoma et al., 2007). C57BL/6 (B6) mice were
infected subcutaneously with MMTV and compared to infections
of A3-mutant mice created by gene trap technology. The mutant
(designated A3/) expressed an in-frame fusion of the ﬁrst four
A3 exons to the β-galactosidase gene and was conﬁrmed to lack
deaminase activity as well as inhibitory activity after packaging
into HIV virions. Since MMTV must infect and activate B and T cells
during transmission to target mammary epithelial cells (Golovkina
et al., 1992, 1998; Held et al., 1993a, 1993b), lymphocytes were
examined in infected mice in the presence and absence of
functional A3. Two-fold higher levels of activated B and T cells
were observed in A3 / mice at 4–6 days post-infection compared
to those obtained from wild-type or heterozygous mice, consistent
with a dominantly active A3 enzyme. Levels of MMTV DNA in
lymph nodes also were increased by 10-fold in the homozygous
A3-mutant animals (Okeoma et al., 2007). Interestingly, A3 char-
acteristic G-to-A mutations were rarely found in MMTV sequences,
implying that this virus restriction mechanism may be largely and
possibly exclusively deamination-independent (MacMillan et al.,
2013; Nair et al., 2014). Although some mechanistic details remain
to be determined, these experiments clearly demonstrated that
endogenous A3 functions in vivo to limit MMTV infection.
Interestingly, mice express two different A3 isoforms (Abudu
et al., 2006; Jónsson et al., 2006; Li et al., 2012a; Sanville et al., 2010;
Takeda et al., 2008). All nine exons combine to encode a longer
isoform in BALB/c mice, whereas eight exons encode a shorter
isoform in B6 mice due to an exon 5 skip during splicing. Both
isoforms have intact N- and C-terminal deaminase domains but,
unlike the human double-domain enzymes, the N-terminal domain
is responsible for DNA cytosine deamination (Hakata and Landau,
2006; Jónsson et al., 2006; MacMillan et al., 2013). In addition, BALB/
c mice express lower levels of A3 compared to B6 mice, suggesting
that speciﬁc mouse strains, such as BALB/c, may be less restrictive
for the replication of murine retroviruses (Li et al., 2012a; Okeoma et
al., 2009a, 2009b; Sanville et al., 2010; Takeda et al., 2008). A3 mRNA
is expressed in many tissues, including lymphocytes, one of the
major cell types infected by MMTV (Golovkina et al., 1998), thus
providing a primary barrier to the establishment of infection. A3 is
also expressed in mammary epithelial cells, providing a secondary
barrier to the establishment of infection and helping to prevent
milk-borne viral transmission (Okeoma et al., 2010). Therefore, A3
most likely restricts MMTV replication at multiple steps during virus
replication and transmission in vivo. Consistent with function
against both exogenous viruses and endogenous retroelements
(discussed below), A3-knockout mice do not appear to have a defect
in development, survival, or fertility (Mikl et al., 2005).
MuLV restriction
Multiple early studies indicated that murine leukemia viruses
(MuLV) are considerably more resistant to murine A3 than to
enzymes from other species, such as human A3G (Abudu et al.,
2006; Bishop et al., 2004; Langlois et al., 2009; Rulli et al., 2008).
This observation led to suggestions that MuLVs were naturally
resistant to the A3 enzyme of its host species, and that murine A3
was ineffective in controlling these viral infections. However, several
studies have used wild-type and A3-null mice (true knockout and
gene trap models) to demonstrate that A3 restricts MuLV infection
in vivo (Langlois et al., 2009; Low et al., 2009; Mikl et al., 2005;
Takeda et al., 2008). A3-null animals showed 10- to 100-fold
increases in overall numbers of productively Friend (F)-MuLV
infected cells in both the spleen and the bone marrow (Takeda
et al., 2008). Similar overall increases in infected cell numbers and
proportional increases in viral loads were reported for Moloney (M)-
MuLV infection of A3 null animals compared to heterozygous or
wild-type littermates (Low et al., 2009). Furthermore, the differences
between heterozygous and mutant A3 were only observed within
the ﬁrst 10 days after virus introduction (Low et al., 2009). As
anticipated, the presence of two copies of A3 in mice prolonged the
latency of M-MuLV-induced T-cell lymphomas and decreased
metastasis to the kidneys (Low et al., 2009). These results are
consistent with the idea that APOBEC family proteins serve as part
of the innate immune system, which is important at early times after
infection to induce an adaptive response (Moris et al., 2014). Neither
of these MuLV studies, as well as an independent series of experi-
ments (Langlois et al., 2009), reported evidence for MuLV G-to-A
hypermutation by endogenous A3. Nevertheless, more sensitive
methods such as deep sequencing suggest that both MuLV and
MMTV may accumulate low levels of G-to-A mutation (Barrett et al.,
2014; MacMillan et al., 2013; Smith et al., 2011).
Bone marrow-derived cells previously were shown to be
required for efﬁcient M-MuLV infection (Brightman et al., 1990;
Davis et al., 1987; Li and Fan, 1990). Because increased virus levels
also were observed in bone marrow after infection of A3-mutant
mice, primary bone-marrow-derived dendritic cells (BMDCs) were
infected in culture with Moloney virus that had packaged HA-
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tagged A3 Δexon5 (the isoform expressed in B6 mice) (Low et al.,
2009). As anticipated, the presence of B6 A3 reduced the infectiv-
ity of M-MuLV by 2-fold in BMDC lacking functional A3 expres-
sion. More surprising was the observation that infectivity of
M-MuLV with packaged functional A3 (Δexon5) could be reduced
further by infection of BMDCs expressing A3 (Δexon5) (Low et al.,
2009). These data suggested that A3 in the recipient cells could
also suppress the infectivity of murine retroviruses.
Another interesting story emerged from studies of an endogenous
MuLV (AKV). Similar to the work described above for MuLV,
splenocytes and thymocytes puriﬁed from A3-null animals were
410-fold more susceptible to infection by AKV (Langlois et al., 2009).
However, here restriction correlated with a signiﬁcant increase in
viral G-to-A mutations (Langlois et al., 2009). Moreover, since this
experiment was performed ex vivo, this study provides a second clear
example of endogenous A3 restricting the incoming viral particles in
target cells (a still contentious issue discussed further below). Never-
theless, these studies demonstrate that endogenous A3 controls
MuLV infection and pathogenesis in vivo. These conclusions alone
are important but additionally interesting by implying an evolution-
ary advantage for retroviruses to evolve partial resistance, rather than
complete resistance, to A3 restriction and mutagenesis.
The murine A3 locus also has been identiﬁed as the Resistance to
Friend Virus (Rfv3) gene, shown previously to regulate the neutralizing
antibody response to Friend virus infection (Santiago et al., 2008). The
underlying mechanism is complex and not yet fully understood. An
indirect possibility is that the increased antigenic diversity of hyper-
mutated and even non-infectious viruses may provoke stronger AID-
dependent adaptive immune responses (Smith et al., 2011). A direct
explanation is that murine A3 may contribute directly to somatic
mutation of expressed antibody gene DNA sequences and, together
with AID, create more robust antibody responses (Halemano et al.,
2014). This is supported by observations of increased levels of anti-
body gene G-to-A and C-to-T mutations in wild-type compared to A3-
null animals infected in parallel with F-MuLV (Halemano et al., 2014).
However, this single report contrasts with many prior studies
indicating total ablation of antibody gene somatic hypermutation in
AID-null animals that presumably still expressed endogenous A3
(original work by Muramatsu et al. (2000); reviewed in Di Noia and
Neuberger (2007)). In any event, these studies are signiﬁcant because
they highlight potential synergy and crosstalk between the innate A3
restriction system and the adaptive antibody response to retrovirus
infection.
The contribution of murine APOBEC1 and AID to retrovirus
restriction is less clear. One study implicated APOBEC1 in F-MuLV
restriction, as both G-to-A and C-to-T hypermutations were detected
in 50-TC motifs using differential DNA denaturation PCR (3D-PCR) of
genomic DNA samples at multiple time points after infection of
newborn OF-1/Swiss mice (Petit et al., 2009). In contrast, a more
recent study infected B6 animals with Friend virus complex,
evaluated acute infection levels, and found no discernable difference
between APOBEC1 wild-type and null animals (Barrett et al., 2014).
APOBEC1-null animals were also analyzed in parallel with A3-null
animals in the AKV study described above, and G-to-A mutation
levels were not above background by deep sequencing (Langlois et
al., 2009). Together, these results suggest that A3, but not APOBEC1,
restricts F-MuLV infectivity and causes hypermutations during viral
replication in mice. Strain-speciﬁc differences between Swiss versus
B6 mice may explain these observed differences. In addition,
Abelson MuLV infection of mice induced AID in non-germinal center
B cells, which then triggered the DNA-damage response and
restricted proliferation of infected cells (Gourzi et al., 2006, 2007).
Since no viral G-to-A mutations were observed, these data suggest
that APOBEC family members may use multiple mechanisms to
activate innate immunity to viruses.
A3 counteraction mechanisms of murine retroviruses
As mentioned above, several studies have indicated that murine
retroviruses are more resistant to murine A3 than to enzymes from
other species, such as human A3G (Abudu et al., 2006; Bishop et al.,
2004; Langlois et al., 2009; Rulli et al., 2008). Analogous to the A3
counteraction mechanism of HTLV-1, some work has indicated a
virion exclusion mechanism in which cytoplasmic A3 is simply not
packaged into assembling particles (Abudu et al., 2006; Doehle et al.,
2005). In support of this idea, cell culture studies with epitope-
tagged proteins have indicated that murine A3 packages into MuLV
particles less efﬁciently than human A3G. In addition, MuLV pro-
tease may cleave packaged A3 and provide a second layer of defense
against restriction (Abudu et al., 2006).
Recent data indicate that glyco-Gag affords protection from the
anti-viral effects of murine A3 (Boi et al., 2014; Kolokithas et al.,
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Fig. 3. Model for glyco-Gag protection from restriction by murine A3. The left image depicts glyco-Gag as an oblong blue shape that prevents A3 from accessing reverse
transcription complexes. Capsids are primarily composed of the classical Gag (circles not depicted on the left panel). The right panel depicts Gag as a blue oval that causes the
capsid to be more loosely formed and susceptible to the A3-mediated block in reverse transcription. Although low levels of G-to-A mutation have been reported, these
changes are a minor outcome of A3 activity and are not depicted for clarity. See the text for additional details.
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2010; Nitta et al., 2012; Stavrou et al., 2013). Almost all MuLVs
encode a longer glycosylated form of the capsid precursor protein
Gag (glyco-Gag), which originates from translation initiation at a
CUG start codon upstream of the normal cytoplasmic Gag start
codon (Berlioz and Darlix, 1995). This glyco-Gag protein has an N-
terminal 88 amino acid extension with a signal peptide that directs
synthesis of the protein across the ER membrane, allowing
glycosylation and transport to the cell surface. Subsequently, the
glycosylated Gag is cleaved into two proteins of 55 and 45 kDa.
The N-terminal 55 kDa product is maintained as a type II trans-
membrane protein, which is necessary for a late step of viral
assembly as well as neurovirulence, whereas the C-terminal
45 kDa protein is released from cells (Fujisawa et al., 1997; Low
et al., 2007). Glycosylation and post-translational processing may
differ according to the cell type infected (Fujisawa et al., 1997).
Several studies have shown that glyco-Gag defective particles are
less infectious than wild-type MuLV particles (Boi et al., 2014;
Kolokithas et al., 2010; Nitta et al., 2012; Stavrou et al., 2013). This
restriction phenotype is largely alleviated in A3-deﬁcient cells and
animals (Boi et al., 2014; Kolokithas et al., 2010; Stavrou et al., 2013).
Moreover, glyco-Gag-defective viruses reverted to wild-type func-
tion during infections of A3-expressing animals, but not A3-null
animals, demonstrating the importance of glyco-Gag in antagonizing
A3-dependent restriction (Stavrou et al., 2013). Recent data have also
indicated that loss of N-linked glycosylation sites in glyco-Gag
results in increased hypermutation by A3 (Rosales Gerpe et al.,
2015). Interestingly, glyco-Gag-mutant virions are less stable than
wild-type particles during ultracentrifugation with detergent
(Stavrou et al., 2013). Further, A3 incorporation during cell culture
and in vivo replication caused defects in reverse transcription when
glyco-Gag was absent (Boi et al., 2014; Stavrou et al., 2013). These
studies combined to suggest a mechanism in which glyco-Gag
stabilizes the viral core and shields viral reverse transcription
complexes from the restrictive activities of A3, as well as affording
protection from other innate immune effector proteins such as the
DNA nuclease Trex1 (Stavrou et al., 2013) (Fig. 3).
A3 counteraction mechanisms of other retroviruses
The foamy viruses (FVs) use the Bet protein to antagonize
APOBEC. Bet, like Vif, is encoded at the 30 end of the retroviral
genome and is not required for virus replication in cell lines
(Baunach et al., 1993). Mutations in the feline FV bet open reading
frame lead to reduced viral titers in CRFK (feline) cells expressing
feline A3s and increased G-to-A hypermutations (Lochelt et al.,
2005). Nevertheless, Bet has no sequence homology to Vif and
appears to act by a different mechanism than either Vif or glyco-Gag
(Chareza et al., 2012; Lochelt et al., 2005; Russell et al., 2005). Unlike
Vif, which acts as an adapter between APOBEC and an E3 ligase, Bet
does not induce A3 degradation, but prevents packaging of parti-
cular A3s into foamy virus particles. Feline FV Bet has been shown to
bind to feline A3 (Lochelt et al., 2005), and prototype FV Bet can
prevent human A3G dimerization and function (Jaguva Vasudevan
et al., 2013; Perkovic et al., 2009; Russell et al., 2005). Bioinformatic
analysis has identiﬁed six conserved motifs encoded within the bel2
portion of the bet mRNA, and these motifs appear to be required for
creating high afﬁnity complexes between Bet and A3 (Lukic et al.,
2013). Interestingly, Bet is expressed at high levels in infected cells,
both in culture and in animals, consistent with inactivation of A3 by
Bet binding or sequestration (Alke et al., 2001; Lukic et al., 2013). In
addition, A3s may be able to inhibit FV replication in both producer
as well as target cells (Lochelt et al., 2005), which may be linked to
the fact that spumaviruses can initiate reverse transcription in
producer cells (Moebes et al., 1997). Therefore, FVs antagonize
A3-induced hypermutation using a mechanism distinct from those
described above.
Interestingly, the betaretroviruses lack a common mechanism to
avoid APOBEC-mediated restriction. For example, the Mason–Pﬁzer
monkey virus (MPMV) has been reported to be resistant to expres-
sion of rhesus monkey A3G by excluding this enzyme from virions
(Doehle et al., 2006). The mechanism for A3G exclusion is unclear.
Nevertheless, mouse A3, but not rhesus A3G, is bound by MPMV Gag
and packaged into viral particles where it inhibits viral infectivity
(Doehle et al., 2006). In contrast, the betaretrovirus MMTV packages
A3, which then blocks subsequent reverse transcription (MacMillan
et al., 2013). Like many MuLVs, the packaged A3 caused only low-
level hypermutation of the proviruses that escaped A3 inhibition
(MacMillan et al., 2013). Effects of A3 on MMTV replication were
most apparent in mouse strains that express high levels of this
deaminase (Okeoma et al., 2009b), whereas the related TBLV, which
has an altered LTR and induces T-cell lymphomas, replicates well in
mouse strains that express either high or low levels of A3 (Bhadra
et al., 2009; Meyers et al., 1989; Mustafa et al., 2003). Furthermore,
unlike MPMV, MMTV, and TBLV, complex retroviruses express a
doubly spliced mRNA and the Rem precursor protein (Indik et al.,
2005; Mertz et al., 2005). The Rem precursor is cleaved into an
N-terminal signal peptide (Rem-SP) that serves a Rev-like function,
whereas the function of the C-terminal 203 amino acid protein has
not been determined (Byun et al., 2010, 2012). One possibility is that
the activity of the Rem precursor or the C-terminus provides the role
of the glycosylated Gag protein of MuLVs.
APOBEC3 involvement in endogenous virus and transposon
restriction
Although the role of APOBECs as anti-viral factors was initially
shown with exogenous retroviruses, including HIV-1, subsequent
studies demonstrated fundamental roles for these enzymes in sup-
pressing the mobilization of endogenous retroviruses and retrot-
ransposons. These parasitic elements occupy a large fraction of the
human genome and, although mostly defective, the remaining func-
tional elements must be exquisitely controlled to prevent excessive
genome damage and potential genetic catastrophe.
One major family of endogenous parasites that is controlled by
APOBEC proteins is comprised of autonomous LINE-1 (L1) transpo-
sons and related non-autonomous Alu transposons, which require L1
gene products for transposition. These elements rely on integration-
primed reverse transcription for copying from one location of the
genome and inserting in another (i.e., copy and paste mechanism).
Initial studies demonstrated L1 restriction by overexpressing various
A3 and AID members in cell culture experiments (Bogerd et al.,
2006b; Chiu et al., 2006; Kinomoto et al., 2007; MacDuff et al., 2009;
Muckenfuss et al., 2006; Stenglein and Harris, 2006). Restriction did
not correlate with A3 localization to the nuclear compartment, where
L1 reverse transcription occurs (Stenglein and Harris, 2006). In all of
these instances, the inhibition of transposition occurred without
detectable G-to-A mutation, suggesting that the major mechanism of
inhibition may be linked to the strong RNA-binding activity of these
enzymes. Consistent with this idea, AID overexpression inhibited
production of L1 ORF1 (equivalent to Gag capsid proteins; Metzner
et al., 2012). However, a recent study blocked uracil DNA repair and
observed some L1 G-to-A mutation (Richardson et al., 2014). Thus,
similar to other examples discussed earlier, the mechanism of L1 and
Alu restriction by A3 family members may involve both deaminase-
dependent and -independent activities.
However, a major drawback to the aforementioned studies is a
dependence on A3/AID overexpression and L1/Alu transposition
from a reporter plasmid inserted into chromosomal DNA. Only two
studies have attempted to address the impact of endogenous A3
enzymes on transposition. One study depleted endogenous A3B in
both HeLa and human embryonic stem cell lines and observed a
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signiﬁcant 3 to 5-fold increase in L1 transposition from a trans-
fected reporter plasmid (Wissing et al., 2011). The second study
reported an inverse correlation between L1 mobility in primates
and expression levels of endogenous A3B and PiWi proteins
(Marchetto et al., 2013). Thus, more work will be necessary to
establish the precise mechanisms and the identities of the A3
family members that are most relevant to suppressing the trans-
position of L1 and Alu elements.
Endogenous retroviruses are also substrates for restriction and
hypermutation by A3 family members. Like exogenous viruses, but
unlike L1/Alu elements, these parasites require long-terminal
repeats (LTRs) for reverse transcription and gene expression, most
of which are inactive (Bannert and Kurth, 2004). Initial studies
demonstrated that mouse intracisternal A particles (IAPs) and MusD
elements are susceptible to restriction and hypermutation by
overexpressed A3 enzymes (Bogerd et al., 2006a; Esnault
et al., 2005, 2006). Interestingly, the inhibition and hypermutation
of LTR-dependent elements are also observed by overexpressing A3
enzymes in heterologous systems, as evidenced by suppression of
Ty1 element replication in yeast (Dutko et al., 2005; Schumacher
et al., 2005). These studies suggest that at least one aspect of the
restriction mechanism does not require additional mammalian
proteins as cofactors. Although most mechanistic studies have been
performed in model systems, bioinformatics approaches have
revealed that signiﬁcant fractions of some, but not all, endogenous
retroviruses have been rendered inactive by a G-to-A hypermuta-
tion mechanism, most likely mediated by A3 enzymes based on
hallmark signatures (Anwar et al., 2013; Jern and Cofﬁn, 2008; Jern
et al., 2007; Lee et al., 2008).
DNA viruses and the APOBEC family
Although the vast majority of information about APOBEC
inhibition of viruses pertains to retroviruses and retroelements,
APOBEC has been reported to be a restriction factor for multiple
DNA-containing viruses (reviewed by Moris et al. (2014)). Hepa-
titis B virus (HBV) is one of the most studied instances of APOBEC-
mediated inhibition of a DNA virus. HBV is a pararetrovirus that is
a major cause of liver cirrhosis and cancer (Beggel et al., 2013;
Bonvin and Greeve, 2008). Similar to foamy virus, HBV has a
reverse transcriptase that copies packaged pregenomic RNA into
DNAwithin the nascent capsid of the producer cells (Jones and Hu,
2013). Unlike retroviruses, the reverse trascriptase is covalently
attached to the 50 end of the minus-strand DNA and does not fully
complete plus strand synthesis within producer cells. The remain-
ing single-stranded DNA region represents a natural target for
APOBEC family enzymes (Beggel et al., 2013). An initial report
using Huh7 hepatoma cells suggested that HBV DNA does not
exhibit G-to-A hypermutation after transfection of A3G, but that
pregenomic RNA was inefﬁciently packaged (Seppen, 2004; Turelli
et al., 2004). A3G appeared associated with viral cores in the
cytoplasm, and similar observations were made for A3B, A3C, A3F,
and A3G in another hepatoma cell line (Suspène et al., 2005;
Turelli et al., 2004). Further investigation revealed that G-to-A
hypermutations were observed at low frequencies (o1 in 10
genomes) using transfection of HBV and A3G in another hepatoma
cell line (Rosler et al., 2004). Both G-to-A and C-to-T substitutions
were observed with A3B, A3F, and A3G, but not A3C, suggesting
that both strands of HBV DNA may be susceptible to deamination
(Suspène et al., 2005). AID also has been reported to be associated
with an HBV ribonucleoprotein complex and to deaminate viral
RNA in tissue culture experiments (Liang et al., 2013). Recent
experiments have interrogated endogenous APOBEC3 proteins in
multiple cell culture models. Treatment of hepatocyte cells with
interferon α or an antibody to crosslink the lymphotoxin β receptor
results in induction of A3A and A3B, respectively, and in G-to-A
hypermutations and clearance of HBV covalently closed circular
DNA (cccDNA) replication intermediates (Lucifora et al., 2014).
Thus, analysis of cell culture models of HBV infection has indicated
roles for multiple APOBEC family proteins in virus restriction.
Analysis of patients chronically infected with HBV paints a
somewhat different picture of APOBEC restriction. A3G levels
appear to be low in primary hepatocytes, but can be induced by
interferon α (Bonvin et al., 2006). In addition, human A3B, A3C,
A3G, A3H, and AID mRNAs are upregulated by inﬂammation,
which often accompanies viral infection (Endo et al., 2007;
Vartanian et al., 2010). HBV may replicate in non-hepatic cells,
although replication in hematopoietic cells appears to be extre-
mely low (Rosler et al., 2004; Untergasser et al., 2006). HBV DNA
sequences from the livers of four patients with high levels of
viremia were enriched by 3D-PCR (Suspène et al., 2005). Two of
these patient samples gave PCR products at a denaturation
temperature of 90 1C, and sequencing of these products revealed
that a small number had G-to-A mutations. The context of these
mutations was consistent with the preference of A3G (Suspène et
al., 2005). In another study, DNA samples were obtained from
patients with liver cirrhosis and analyzed by 3D-PCR at 88.7 1C.
Fifteen of 17 DNAs were ampliﬁed under this condition, and ﬁve
were cloned and sequenced (Vartanian et al., 2010). G-to-A
mutations were observed in HBV minus strands with a sequence
context consistent with A3G activity. The remainder of the muta-
tions showed a sequence context more typical of A3C, rather than
AID (Vartanian et al., 2010). Deep sequencing also was performed
on PCR products obtained in reactions with a 95 1C denaturation.
Four of ﬁve samples showed G-to-A hypermutation varying from
10% to 35% in the X gene, which is single-stranded in virions
(Vartanian et al., 2010). Taken together with the fact that mutated
sequences are rarely recovered by normal high denaturation
temperature PCR, the level of HBV hypermutation appears to be
signiﬁcantly lower than that reported for a number of retroviruses.
Data from several laboratories have indicated that loss of the
pre-capsid (core) antigen may be due to APOBEC-mediated editing
(Noguchi et al., 2007; Turelli et al., 2004; Vartanian et al., 2010).
Serum samples from 47 HBeAg-positive and 33 HBeAg-negative
treatment-naïve patients were subjected to deep sequencing
(Beggel et al., 2013). Hypermutation rates were ca. 15-fold greater
in HBeAg-negative patients and were preferentially in the HBV
virion-associated single-stranded region. Similar to other studies,
the context of the G-to-A mutations suggested editing by A3G
(Beggel et al., 2013; Vartanian et al., 2010). Because pre-core
antigen expression is associated with high viremia and the coding
region contains several optimal sites for APOBEC-mediated muta-
tion, seroconversion to HBeAg negativity may well represent
innate immune selection for particular HBV variants (Beggel
et al., 2013; Vartanian et al., 2010).
Interestingly, transfusion-transmitted virus (TTV) found in the
blood of healthy patients and in HBV carriers contains G-to-A
hypermutations, indicating that viruses that lack reverse tran-
scriptase can be subjected to APOBEC family restriction (Tsuge
et al., 2010). TTV is a single-stranded negative-sense DNA virus,
which is predicted to be a good target for A3 enzymes (Irshad
et al., 2006). In addition, single-stranded DNA viruses belonging to
the parvovirus family can be restricted by APOBEC, particularly
A3A (Chen et al., 2006; Narvaiza et al., 2009). Curiously, two
different parvoviruses are inhibited by A3A, suggesting a con-
served mechanism, yet inhibition appears independent of catalytic
activity (Narvaiza et al., 2009).
Double-stranded DNA viruses may also be substrates for
APOBEC family members. Double-stranded DNA viruses may yield
exposed single-stranded DNA during transcription or genome
replication. Human papilloma viruses (HPVs) for example are
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sexually transmitted, and about 24 of the 300 genotypes are
associated with human cancers (Zur Hausen, 2008). HPV types
1a and 16 in plantar skin warts and precancerous cervical lesions
were shown to have hypermutations (Vartanian et al., 2008). A3A,
A3B, and A3H are expressed in keratinocytes, where HPV has been
shown to replicate. Further, co-transfection experiments have
shown that overexpression of these enzymes could induce HPV
hyperediting (Vartanian et al., 2008).
Recent studies also have documented APOBEC-mediated 50-TC-
to-TT hypermutation signatures in numerous cancers, including
HPV-associated cervical and head-and-neck squamous cell carcino-
mas (HNSCCs) (Alexandrov et al., 2013; Burns et al., 2013; Roberts et
al., 2013). HNSCCs are particularly informative because some are
HPV positive and others are HPV negative. Higher overall levels of
APOBEC signature mutations are observed in HPV positive cancers
(Henderson et al., 2014; Vieira et al., 2014). In addition, hotspots for
APOBEC mutagenesis and oncogene activation occur in PIK3CA,
which encodes the catalytic subunit of a phosphoinositide-3-kinase
that is activated in large proportions of cervical and HNSCCs
(Henderson et al., 2014). These hypermutations are most likely
due to A3B, and possibly A3A, because these are the only family
members induced by HPV infection (Vieira et al., 2014; Warren et
al., 2015). Thus, it is tempting to speculate that cancer mutagenesis
may be the result of collateral DNA damage of an antiviral response
to HPV infection.
DNA viruses that infect B cells also might be expected to be
inhibited by AID since this family member is activated in the
germinal centers to trigger adaptive responses to infection. In
addition, AID can be activated in non-B-cells that normally lack
AID expression by pathogen expression (Gourzi et al., 2006,
2007). Such viruses have been shown to inhibit AID function
through mechanisms distinct from those described for retro-
viruses. Epstein-Barr virus (EBV) is a herpes virus (double-
stranded DNA) that replicates in B cells. This virus antagonizes
the effects of AID by upregulation of a host regulatory microRNA
(miR-155) and the latency-associated protein EBNA2 (Tobollik et
al., 2006). Kaposi's sarcoma herpes virus (KSHV) also infects B
cells (Mesri et al., 1996), and infection of tonsillar B cells
upregulates AID (Bekerman et al., 2013). KSHV often maintains
its genome in a latent state, which requires the expression of four
proteins and 12 microRNAs (Cai et al., 2005; Dittmer et al., 1998;
Pfeffer et al., 2005; Samols et al., 2005). Latency prevents viral
DNA replication and associated AID damage, but AID expression
activates KSHV lytic replication and loss of infectivity (Bekerman
et al., 2013). To antagonize AID, KSHV encodes two different miRs
that bind to the 30 UTR of AID mRNA. Binding of viral miRs at
several different sites is believed to block translation of AID and
triggering of the innate immune response to KSHV (Bekerman
et al., 2013).
Not all DNA viruses have been shown to be susceptible to
APOBEC-mediated restriction. Vaccinia virus does not appear to be
inhibited by APOBEC family members, perhaps due to the seques-
tration of its replication complex in cytoplasmic bodies (Kremer
et al., 2006). Therefore, DNA viruses may avoid APOBEC-mediated
restriction by encoding an inhibitor, preventing incorporation into
virions, avoiding induction of inﬂammation and APOBEC enzymes,
replication in cells with low levels of APOBEC, or replicating in
privileged subcellular locations.
Conclusions
In this review, we have summarized the extraordinary func-
tions of the APOBEC family of proteins, including participating in
antibody diversiﬁcation, editing of mRNA, and acting as retrovirus
and retrotransposon restriction factors. Moreover, mechanisms for
inhibition of parasites are diverse, including both deamination-
dependent and -independent processes. For their part, viruses
have responded with a variety of strategies to circumvent restric-
tion from poly-ubiquitination and degradation mechanisms to
exclusion and protection mechanisms. It is likely that many more
A3 antagonizing measures exist and await discovery. An overall
picture is emerging in which the A3 family members, including
AID and APOBEC1, provide an overlapping defense against a wide
variety of parasitic elements. This is important for controlling
endogenous elements, but also for protecting against exogenous
viral infections as well as from zoonotic transmissions. Nearly
every DNA-based parasite may be susceptible and, if so, invariably
evolved at least one protective measure. Many protective mea-
sures have been described thus far and undoubtedly several more
await discovery. Clearly, there is still much work to be done, and
this story has no ﬁnite ending.
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